- Home
- SRFM vs FATE Comparison
SRFM vs FATE Comparison
Compare SRFM & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRFM | FATE |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 125.6M |
| IPO Year | 2023 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SRFM | FATE |
|---|---|---|
| Price | $1.16 | $1.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $3.25 | ★ $4.10 |
| AVG Volume (30 Days) | ★ 2.2M | 1.3M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.69 | 29.88 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,557,000.00 | $6,646,000.00 |
| Revenue This Year | $25.90 | N/A |
| Revenue Next Year | $20.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.04 | $0.83 |
| 52 Week High | $9.35 | $1.94 |
Technical Indicators
Market Signals| Indicator | SRFM | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 44.65 |
| Support Level | $1.04 | $1.06 |
| Resistance Level | $2.16 | $1.30 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 25.93 | 40.74 |
Price Performance
Historical ComparisonAbout SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.